— Know what they know.
Not Investment Advice
Also trades as: BIO (NYSE) · $vol 107M

BIO-B NYSE

Bio-Rad Laboratories, Inc.
1W: +4.2% 1M: +4.0% 3M: +22.7% YTD: +22.1% 1Y: +18.2% 3Y: -6.2% 5Y: -36.8%
$379.50
+15.35 (+4.22%)
 
Weekly Expected Move ±0.3%
$364 $365 $366 $367 $368
NYSE · Healthcare · Medical - Devices · Tech Score Buy · Power 69 · $9.9B mcap · 522410 float · 0.017% daily turnover
Credit Risk of going bust: lower than 70% of companies Debt: 10.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $4.62 (down 99%), Bio-Rad Laboratories, Inc. would be worth roughly what it owes.
Total debt $1.20B against a stock market value of $10.19B.
Distance to default 7.62 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $802.2M (short-term plus half of long-term), stock volatility 36.7%; Altman Z 3.86. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Balance Sheet Trends

Total Assets
$10.6B +12.9% ▲
5Y CAGR: -4.0%
Total Liabilities
$3.1B +11.7% ▲
5Y CAGR: +0.2%
Shareholders Equity
$7.5B +13.5% ▲
5Y CAGR: -5.5%
Cash & Investments
$1.5B -7.3% ▼
5Y CAGR: +9.3%
Total Debt
$1.5B +11.4% ▲
5Y CAGR: +46.6%
Net Debt
$999M +12.7% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$471M$434M$404M$488M$532M
Short-Term Investments$399M$1.4B$1.2B$1.2B$1.0B
Cash & ST Investments$870M$1.8B$1.6B$1.7B$1.5B
Net Receivables$424M$495M$489M$452M$472M
Inventory$572M$719M$780M$760M$741M
Other Current Assets$16M$29M$32M$31M$14M
Total Current Assets$2.0B$3.2B$3.0B$3.0B$2.9B
Property, Plant & Equip.$716M$680M$724M$689M$710M
Goodwill & Intangibles$601M$739M$734M$704M$754M
Long-Term Investments$14.4B$8.8B$7.7B$4.8B$6.1B
Other Non-Current Assets$104M$95M$95M$102M$102M
Total Non-Current Assets$15.8B$10.3B$9.3B$6.3B$7.7B
Total Assets$17.8B$13.5B$12.3B$9.4B$10.6B
— Liabilities —
Accounts Payable$142M$135M$145M$122M$129M
Short-Term Debt$489K$465K$500K$1M$38M
Deferred Revenue$51M$52M$0$0$0
Other Current Liabilities$128M$117M$162M$147M$141M
Total Current Liabilities$681M$569M$523M$468M$517M
Long-Term Debt$11M$1.2B$1.2B$1.2B$1.3B
Other Non-Current Liab.$182M$196M$195M$177M$53M
Total Non-Current Liabilities$3.4B$3.3B$3.0B$2.3B$2.6B
Total Liabilities$4.1B$3.9B$3.6B$2.8B$3.1B
— Equity —
Common Stock$3K$3K$0$0$0
Retained Earnings$13.5B$9.9B$9.3B$7.4B$8.2B
Accumulated OCI-$176M-$467M-$336M-$538M-$189M
Total Stockholders Equity$13.7B$9.6B$8.7B$6.6B$7.5B
Total Liabilities & Equity$17.8B$13.5B$12.3B$9.4B$10.6B
— Key Metrics —
Total Debt$223M$1.4B$1.4B$1.4B$1.5B
Net Debt-$247M$954M$1.0B$887M$999M
Total Investments$14.8B$10.2B$8.9B$6.0B$7.1B

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms